Abivax SA, a prominent biotechnology company headquartered in Paris, France, continues to make significant strides in the healthcare sector, particularly in the development of anti-viral therapies and therapeutic vaccines. As of June 28, 2026, the company’s stock is actively traded on the NYSE Euronext Paris, with a close price of 84.5 EUR on June 25, 2026. Despite a challenging year marked by a 52-week low of 6.2 EUR on June 29, 2025, and a high of 132 EUR on January 11, 2026, Abivax SA maintains a robust market capitalization of 6.47 billion EUR.
The company’s strategic focus on infectious diseases in Asia and Latin America positions it uniquely in the biotechnology landscape. Abivax SA’s flagship product, ABX 464, is currently in Phase II clinical trials, aiming to provide sustained viral remission or a functional cure for patients with HIV/AIDS. This innovative approach underscores the company’s commitment to addressing some of the most pressing global health challenges.
In addition to ABX 464, Abivax SA is advancing ABX 203, a therapeutic vaccine candidate in Phase IIb/III trials for chronic hepatitis B. The company’s pipeline also includes ABX 196, an art immune enhancer candidate that has successfully completed Phase I clinical trials for iNKT cells. These developments highlight Abivax SA’s dedication to pioneering new therapeutic solutions.
The company’s vaccine development efforts extend to typhoid, meningitis B and C, and leptospirosis, further demonstrating its comprehensive approach to combating infectious diseases. Pre-clinical programs are also underway, with ABX 220 targeting Dengue fever, ABX 544 focusing on Ebola through polyclonal antibodies, and ABX 311 aimed at treating Chikungunya.
Abivax SA’s collaborative efforts are evident through its license contracts with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. Additionally, the company’s partnership with the Cuban Centro de Ingenia Genetica y de Biotecnologia underscores its commitment to international collaboration in advancing biotechnological research and development.
Incorporated in 2013, Abivax SA has established itself as a key player in the biotechnology industry, with a clear vision for the future. The company’s ongoing clinical trials and pre-clinical programs reflect its strategic focus on innovation and its potential to make a significant impact on global health. As Abivax SA continues to navigate the complexities of the biotechnology sector, its forward-looking perspective and collaborative approach position it well for continued growth and success. For more information, stakeholders and interested parties can visit the company’s official website at www.abivax.com .
